RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer

Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKI), including gefitinib, provide a significant clinical benefit in non-small-cell lung cancer (NSCLC) patients, the acquisition of drug resistance has been known to limit the efficacy of EGFR-TKI therapy. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneto, Naoki, Yokoyama, Satoru, Hayakawa, Yoshihiro, Kato, Shinichiro, Sakurai, Hiroaki, Saiki, Ikuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317907/
https://www.ncbi.nlm.nih.gov/pubmed/24750242
http://dx.doi.org/10.1111/cas.12425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317907/
https://www.ncbi.nlm.nih.gov/pubmed/24750242
http://dx.doi.org/10.1111/cas.12425

Ejemplares similares